阿昔洛韦联合丙种球蛋白治疗重症水痘的疗效和安全性观察

Curative effect and safety research of acyclovir combined with intravenous immunoglobulin for severe varicella

目的:探讨阿昔洛韦联合丙种球蛋白治疗重症水痘的疗效和安全性。方法:将64例重症水痘患儿分为阿昔洛韦联合丙种球蛋白组、阿昔洛韦组和利巴韦林联合丙种球蛋白组,比较3组的退热、疱疹结痂以及住院时间。结果:阿昔洛韦联合丙种球蛋白组的退热、疱疹结痂及住院时间均短于另外2组(P<0.01或P<0.05),未见不良反应。结论:阿昔洛韦联合丙种球蛋白对重症水痘具有较好的疗效和安全性。

OBJECTIVE To explore the curative effect and security research of acyclovir combined with intravenous immunoglobulin to treat severe varicella. METHODS The 64 severe varicella children patients were randomly divided into three groups： acyclovir group, acyclovir combined with intravenous imrnunoglobulin and ribovirin combined with intravenous immunoglobulin group, to compare three groups from the time of pyretolysis, herpes to scab and hospitalization. RESULTS Deffervesce time of Acyclovir combined with intravenous immunoglobulin group was shorter than the other two groups （P〈0. 01 or P〈0. 05） in the time of pyretolysis,herpes to scab and hospitalization, no adverse reactions. CONCLUSION Aeyelovir combined with intravenous immunoglobulin to treat severe varicella shows better curative effect and safety.